Clinical trial
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease…
NCT00321854 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00321854 |
|---|---|
| Title | Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | pramipexole |
| Enrollment | 535 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2009 |
| First posted | May 4, 2006 |
| Last update posted | May 16, 2014 |
| Countries | Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: